Compare Aehr Test Systems (AEHR) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aehr Test Systems vs Koninklijke Philips NV — how do they compare? Aehr Test Systems trades at $129.4 (market cap $3.82B), while Koninklijke Philips NV trades at $26.84 (market cap $26.58B). The key difference: Koninklijke Philips NV is far larger — about 7× Aehr Test Systems's market cap, and Koninklijke Philips NV pays a 3.75% dividend while Aehr Test Systems pays none. Which is the better fit depends on your goals.
| AEHR | PHG | |
|---|---|---|
Market Cap | $3.82B | $26.58B |
Sector | Technology | Health |
52-Week High | $117.18 | $32.91 |
52-Week Low | $17.38 | $25.02 |
Enterprise Value | $3.72B | $33.13B |
Dividend Yield | — | 3.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AEHR Test Systems (AEHR) surged 25.02% to $132.77, driven by strong earnings beats and a $22 million follow-on order for AI processor wafer-level burn-in systems (Accesswire, August 12, 2026). The stock exhibits bullish technical signals with support at $112 and resistance at $129, though RSI suggests overbought conditions. Revenue reached $58.97 million in 2025, but net income remained negative at -$3.91 million, reflecting high growth investments.
Outlook is optimistic due to AI and silicon photonics demand, with FY27 revenue growth projected at 160–200% (Seeking Alpha, July 18, 2026). Risks include customer concentration and negative cash flow. Analysts are mixed (33% buy, 67% hold), highlighting valuation concerns at a P/S of 71.87. Upside potential exists if execution aligns with backlog growth.
PHG trades at $26.86, down 0.3% on the day, with a bullish technical signal supported by moving averages. The company shows improving fundamentals with three consecutive quarterly earnings beats and a return to profitability in 2025 after previous losses. Recent news highlights Exor's potential stake increase to 22% and FDA clearances for new medical devices, while analyst sentiment remains mixed with 41% buy ratings.
The outlook appears cautiously optimistic with solid earnings momentum and institutional accumulation, though risks include order intake volatility and competitive pressures. The stock offers value characteristics with reasonable P/E of 20.5 and strong cash flow generation, but investors should monitor execution on growth initiatives and margin sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aehr Test Systems
Aehr Test Systems provides testing and burn-in solutions for the semiconductor industry. Its systems ensure the reliability of AI processors, data center chips, and electric vehicle components at the wafer and package levels.
Read more on AEHR →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
